Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation.

Schwager, Simon; Renner, Silvana; Hemmerle, Teresa; Karaman, Sinem; Proulx, Steven T.; Fetz, Roman; Golding-Ochsenbein, Alexandra Michaela; Probst, Philipp; Halin, Cornelia; Neri, Dario; Detmar, Michael (2018). Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation. JCI insight, 3(23) JCI Insight 10.1172/jci.insight.124850

[img] Text
124850.1-20181120134926-covered-253bed37ca4c1ab43d105aefdf7b5536.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (15MB) | Request a copy

VEGF-C is an important mediator of lymphangiogenesis and has been shown to alleviate chronic inflammation in a variety of disease models. In this study, we investigated whether targeted delivery of VEGF-C to sites of inflammation and site-specific activation of lymphatic vessels would represent a clinically feasible strategy for treating chronic skin inflammation. To this end, we generated a fusion protein consisting of human VEGF-C fused to the F8 antibody (F8-VEGF-C), which is specific for the alternatively spliced, angiogenesis-marking extradomain A (EDA) of fibronectin. In two mouse models of psoriasis-like skin inflammation, mediated by transgenic VEGF-A overexpression or repeated application of imiquimod, intravenous treatment with F8-VEGF-C but not with untargeted VEGF-C significantly reduced ear skin edema and was as effective as the clinically used TNF-α receptor-Fc fusion protein (TNFR-Fc). Treatment with F8-VEGF-C led to a marked expansion of lymphatic vessels in the inflamed skin and significantly improved lymphatic drainage function. At the same time, treatment with F8-VEGF-C significantly reduced leukocyte numbers, including CD4+ and γδ T cells. In sum, our results reveal that targeted delivery of VEGF-C and site-specific induction of lymphatic vessels represent a potentially new and promising approach for the treatment of chronic inflammatory diseases.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Theodor Kocher Institute

UniBE Contributor:

Proulx, Steven Thomas

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

2379-3708

Publisher:

JCI Insight

Language:

English

Submitter:

Ursula Zingg-Zünd

Date Deposited:

21 Nov 2019 10:12

Last Modified:

21 Nov 2019 10:12

Publisher DOI:

10.1172/jci.insight.124850

PubMed ID:

30518687

Uncontrolled Keywords:

Dermatology Fibronectin Skin Therapeutics growth factors

BORIS DOI:

10.7892/boris.135342

URI:

https://boris.unibe.ch/id/eprint/135342

Actions (login required)

Edit item Edit item
Provide Feedback